PMA device
ProVee System for BPH
Proverum, Ltd. · Stent, Urethral, Prostatic, Permanent Or Semi-Permanent (MER, Class III) · First FDA decision Dec 9, 2025, newest Dec 9, 2025Enlarged prostate (BPH)
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
4
Naming "ProVee"
MAUDE reports
0
Brand "ProVee", since 2015
PubMed studies
7
Mentioning "ProVee"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing ProVee System for BPH
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
P250011 · Decided Dec 9, 2025 · 251 days after receipt
Device type: STENT, URETHRAL, PROSTATIC, PERMANENT OR SEMI-PERMANENT (MER) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "ProVee", any status and sponsor, newest update first.
- ProVIDE Studies Post Exit AnalysisRecruiting
ProVerum MedicalNot on our public-company list
NCT07680543 · 25 participants (planned) · Start Sep 30, 2026 · Primary completion Jul 31, 2029
Device: ProVee Urethral Expander System · For: BPH With Symptomatic Lower Urinary Tract Symptoms
Sites: Lake Barrington, Illinois
- ProVee Urethral Expander System IDE Study (ProVIDE)Pivotal-lookingActive, not recruiting
ProVerum MedicalNot on our public-company list
NCT05186740 · 221 participants · Start Jun 9, 2022 · Primary completion Mar 15, 2024
Device: ProVee Urethral Expander System · For: BPH With Symptomatic Lower Urinary Tract Symptoms
Sites: Sacramento, California; Hialeah, Florida; Palm Coast, Florida · 16 sites in all
- ProVIDE II Bridging StudyActive, not recruiting
ProVerum MedicalNot on our public-company list
NCT06236802 · 40 participants · Start Mar 6, 2024 · Primary completion Sep 6, 2024
Device: ProVee device · For: BPH With Symptomatic Lower Urinary Tract Symptoms
Sites: Tampa, Florida; Winter Garden, Florida; Lake Barrington, Illinois · 8 sites in all
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "ProVee", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MER
1 reports: 0 malfunction, 1 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "ProVee"[tiab]. The summary above synthesizes these.
- [Not Available].
Morales-Vazquez F, Cano-Blanco C, Pérez-Quintanilla M, et al. · Salud Publica Mex · 2025Practice Guideline, English Abstract
- State-of-the-art in minimally invasive treatments for benign prostatic obstruction.
Grossmann NC, Berjaoui MB, Choudhary O, et al. · Investig Clin Urol · 2026Review, Research Support, Non-U.S. Gov't
- Minimally invasive techniques in quest of Holy Grail of surgical management of enlarged prostates: a narrative review.
Porto JG, Titus R, Camargo F, et al. · World J Urol · 2024Review
- 12-Month Outcomes From a Randomized, Sham-Controlled Trial Evaluating a Novel Prostatic Urethral Stent for the Treatment of Benign Prostatic Hyperplasia.
Kaplan SA, Parekattil SJ, Wu NZ, et al. · J Urol · 2026Randomized Controlled Trial, Multicenter Study
- Translation into Spanish of: "Changes to publication requirements made at the XVIII International Botanical Congress in Melbourne - what does e-publication mean for you?". Translated by Carmen Ulloa Ulloa, Lourdes Rico Arce, and Renée H. Fortunato Cambios a los requisitos para publicar realizados en el XVIII Congreso Internacional de Botánica en Melbourne - ¿qué significado tiene la publicación electrónica para usted?
Knapp S, McNeill J, Turland NJ · PhytoKeys · 2011
- Minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia.
Wang SL, Herrera CD, Lloyd-Harris JE · Curr Urol Rep · 2026Review
Other devices of this type
Also filed under product code MER.
- Zenflow Spring® Implant and Delivery SystemZenflow, Inc. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.